Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04386070
PHASE3

Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19

Sponsor: University of Birmingham

View on ClinicalTrials.gov

Summary

The aim of this study is to reduce pulmonary complications in adult patients undergoing abdominal or thoracic surgery in COVID-19 exposed hospital environments. A Trial in Low and Middle Income Countries (LMICs)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

281

Start Date

2022-05-16

Completion Date

2023-06-30

Last Updated

2026-11-16

Healthy Volunteers

No

Interventions

DRUG

RESP301

RESP301 is a formulation consisting of three agents already used in clinical practice: mannitol, sodium nitrite and citric acid. Delivered by a vibrating mesh nebuliser three times per day (TID) (at least 4 hours apart), for 7 days. Each dose of RESP301 is a 6ml admixture of 150mM NaNO2, 50mM mannitol and 100mM citric acid, buffered at pH 5.4.

Locations (9)

University Of Abuja Teaching Hospital (Spoke)

Gwagwalada, Nigeria

Lagos University Teaching Hospital (Hub)

Lagos, Nigeria

Nnamdi Azikiwe University Teaching Hospital (Spoke)

Nnewi, Nigeria

University Teaching Hospital of Butare (CHUB) (Spoke)

Butare, Rwanda

Kibungo Referral Hospital (Spoke)

Kibungo, Rwanda

Kibagabaga Hospital (Spoke)

Kigali, Rwanda

University Teaching Hospital of Kigali (Hub)

Kigali, Rwanda

Kibogora District Hospital (Spoke)

Kirambo, Rwanda

Ruhengeri Referral Hospital (Spoke)

Ruhengeri, Rwanda